Immediate Postmastectomy Breast Reconstruction (Strattice Breast)

N/ACompletedNCT00619762

LifeCell17 enrolled

Overview

This prospective, multicenter, open-label study will assess the clinical outcomes of the LTM product in three planned analyses. The primary objective of this study is to prospectively assess the clinical outcomes associated with the use of LTM in two-stage (expander then permanent implant) immediate post-mastectomy breast reconstruction.

nothing to add

Study Type

OBSERVATIONAL

Enrollment

Conditions

Breast Cancer

Interventions

LTM - a porcine-based surgical meshDEVICE

Use of LTM to support weak and/or absent soft tissue to facilitate immediate breast reconstruction postmastectomy

Eligibility

Sex: FEMALEMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * A candidate for immediate, two-stage breast reconstruction using LTM following a skin sparing mastectomy * An ASA Physical Status Classification5 of 1 or 2 (see App I) * Estimated life expectancy \> 1 year Exclusion Criteria: * Clinically significant systemic disease * Received inductive chemo-therapy within 2 months prior to mastectomy or radiation therapy to the region at any time * Predicted excised breast mass of \>750 gms * Co-morbid factors which predispose to postoperative infection, such as insulin dependent diabetes, smoking, chronic steroid use, malnourishment, or co-existent infection * Need for tissue flap in addition to expander * History of alcohol abuse, illicit drug use, significant mental illness, physical dependence to any opioid, or drug abuse or addiction * Enrollment or plans to enroll in another clinical trial during this study that would affect the patient's safety or results of this trial * Any of the conditions identified within the labeled contraindications, i.e. sensitivity to porcine derived products or polysorbate

Locations (5)

Unnamed facility

Washington D.C., District of Columbia, United States

Unnamed facility

Chicago, Illinois, United States

Unnamed facility

Great Neck, New York, United States

Unnamed facility

Willow Grove, Pennsylvania, United States

Unnamed facility

Outcomes

Primary Outcomes

Histology Sample Evaluations Assessing Incorporation of StratticeTM Reconstructive Tissue Matrix

Evaluation of 3 histology parameters, fibroblast infiltration, immune cell response \& revascularization, expressed as frequency distributions. Samples evaluated for presence of fibroblasts (cellularity), neovascularization \& immune cell response using 4 pt scale. Fibroblast Infiltration: 1=None,2=Few,sparse,3=Moderate,4=Dense. Revascularization:1=None,2=Few randomly dispersed capillaries,3=Moderate; mostly homogenous distribution of new vessels,4=Significant,uniformly distributed vessels; both capillaries and arterioles. Immune Cell response: 1= None,2=Few,normal healing response,3=Moderate,4=Significant;above expected presence for healing. 4 high power(HP)fields reviewed \& if uniform in appearance/cellular distribution, 4 considered representative of sample as a whole. If non-uniform distribution observed, 3 HP fields of "sparse or light" distribution \& 3 HP fields of dense distribution counted \& results averaged. Tissue sample then assessed for overall acellularity \& expressed as %.

Time frame: At the time of expander/implant exchange (Stage II),

Secondary Outcomes

Severity of Local Inflammation at and Around the Surgical Site

The Inflammatory response was evaluated by each of the four cardinal signs: erythema, edema, pain and heat, using standard scales for the evaluation of each sign and inflammation as a whole was assessed using a model (AIR Score) which took into account the scores assigned to each of the four signs. A mean score is provided at each timepoint.The minimum total possible score is 4 (less inflamation) and the maximum total possible score is 8 (more inflammation).

Time frame: Postoperative Day 7, 14, 21, 30 days

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.